The trajectory of Sildenafil presents a complex case for stakeholders in the medicinal sector. While initially a tremendous success, producing huge profits, the patent expiration and the subsequent flood of off-brand competitors have significantly affected earnings. This raises questions about the future viability of related therapeutic developm… Read More